C
Cytrellis Biosystems
Medical device for dermatology and more
About Cytrellis Biosystems
Cytrellis is a medical technology startup that operates in the aesthetic devices market. The company is focused on developing and commercializing innovative aesthetic devices that are first in their class. Their primary product is the ellacor® system, a unique and proprietary technology that uses Micro-Coring® to remove sagging skin on a micro-scale. This technology provides aesthetic practitioners with a new way to improve age-related changes in the skin and restore a youthful appearance.
The company's target clients are aesthetic practitioners who are looking for advanced solutions to address skin aging issues. By providing a novel solution to a common problem, Cytrellis is positioning itself as a leader in the aesthetic devices market.
The business model of Cytrellis is based on the development, production, and sale of its proprietary ellacor® system. The company generates revenue by selling these devices to aesthetic practitioners. The potential for recurring revenue also exists in the form of selling replacement parts or upgrades for the system.
In summary, Cytrellis is a promising startup in the aesthetic devices market, offering a unique solution for skin aging problems. Its business model is based on selling its proprietary technology to aesthetic practitioners, providing them with a new tool to improve their services and satisfy their clients' needs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Woburn, United States
- Employees
- 58
- Open positions
- None listed
- Dealroom signal
- 46.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Surgery, Dermatology, Tech for Hospitals and Clinics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2021 | $50M | $200M | ARCH Venture Partners · D1 Capital Partners · PFM Health Sciences | — |
| SERIES BOther financing | Jun 2018 | $29M | $114M | ARCH Venture Partners · PFM Health Sciences · Biomatics Capital Partners | — |
Growth signals
Latest recorded traffic for Cytrellis Biosystems is 1.6K monthly website visits, down 30.4% over the last three months. Cytrellis Biosystems's team grew 13.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
ARCH Venture Partners- PFPartners Innovation Fund
Merz
PFM Health Sciences
Biomatics Capital Partners
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cytrellis Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cytrellis Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.